Prospective Sample Collection for Cancer of Bladder

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Jun 3, 2019

Keywords

ClinConnect Summary

This clinical trial, called the Flemish Databank for Urothelial Cancer, is focused on collecting important medical information from patients who are being treated for bladder cancer. The goal is to gather clinical and pathological data, which means they want to understand more about the disease and how it is treated. This information will help improve future treatment and care for patients with bladder cancer.

To participate in this trial, you need to be between 18 and 90 years old, and both men and women can join. You must also agree to allow the researchers to collect your medical data. Eligible patients are those who are scheduled for specific treatments, such as a type of surgery to remove bladder tumors or other related procedures. If you choose to participate, you will help contribute valuable information that can benefit others in the future. It's important to note that if you decide not to participate or change your mind later, that is perfectly fine, and it won't affect your treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • who are aged between 18-90,
• • who are of male or female sex,
• • who give their informed consent to collect their clinical and pathological data,
• • who are planned to undergo TURBT for BC,
• • who are planned to undergo (salvage) radical cystectomy with or without an extended pelvic lymph node dissection,
• • who are planned to undergo tumor biopsy (from primary or metastatic tumor),
• • who are planned to undergo radical nephroureterectomy ± partial cystectomy or segmental ureterectomy, with or without a lymph node dissection,
• • who are planned to undergo endoscopic tumor biopsy or resection,
• • from whom metastases will be surgically removed.
• Exclusion Criteria:
• • patients who do not give their informed consent to collect their clinical and pathological data,
• • patients who withdraw their informed consent to use their clinical and pathological data,
• • patients who refuse the planned treatment,
• • women who are pregnant or have suspicion of pregnancy.